This need for better understanding especially in the context of current combinatorial cancer therapy is highlighted by the fact that BRCA2-deficient tumors under dual PARP inhibition and MUS81 depletion have improved viability compared to either alone (Rondinelli et al., 2017). This evidence concerns the gene PARP1 and cancer.